A Two-part, Phase 3b, Prospective, Multicenter, Open-label, Randomized, Crossover Study of the PK and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and the Safety of Faster Infusion Rates in Patients With Hemophilia A or B With Inhibitors

Trial Profile

A Two-part, Phase 3b, Prospective, Multicenter, Open-label, Randomized, Crossover Study of the PK and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and the Safety of Faster Infusion Rates in Patients With Hemophilia A or B With Inhibitors

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Factor VIII inhibitor bypassing fraction (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Baxalta
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Jan 2017.
    • 07 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top